C4 Therapeutics. has been granted a patent for Degronimers, which are compounds featuring carbon-linked E3 Ubiquitin Ligase targeting moieties. These can be attached to ligands for targeted in vivo protein degradation, along with methods for their preparation and use. GlobalData’s report on C4 Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on C4 Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. C4 Therapeutics's grant share as of June 2024 was 11%. Grant share is based on the ratio of number of grants to total number of patents.
Degronimers for targeted protein degradation
The granted patent US11992531B2 outlines a series of claims related to a specific compound characterized by a defined chemical formula. The claims detail various structural modifications and selections for the compound, including specific values for substituents (e.g., R7, R8, R15) and linkers, as well as the nature of the targeted proteins. Notably, the patent specifies that the compound can target a range of proteins, including but not limited to the estrogen receptor, androgen receptor, and various kinases and enzymes associated with cancer and other disorders. The claims also encompass a pharmaceutical composition that includes the compound alongside a pharmaceutically acceptable excipient.
Additionally, the patent describes a method for treating disorders mediated by the targeted proteins, emphasizing the administration of an effective amount of the compound or its pharmaceutically acceptable salts. The claims suggest potential applications in treating tumors or cancers, indicating the compound's therapeutic relevance. The specificity of the claims, including the selection of substituents and the identification of targeted proteins, highlights the compound's potential utility in pharmaceutical development and its role in addressing various medical conditions.
To know more about GlobalData’s detailed insights on C4 Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
